Aquestive Therapeutics (AQST) Common Equity (2017 - 2026)

Aquestive Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at -$34.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 44.11% year-over-year to -$34.1 million; the TTM figure through Mar 2026 stood at -$34.1 million (up 44.11% YoY), while the FY2025 annual figure was -$33.7 million, up 44.04% from the prior year.
• Common Equity was -$34.1 million for Q1 2026 at Aquestive Therapeutics, down from -$33.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$4.1 million in Q3 2025 to a low of -$118.6 million in Q4 2022.
• Historically, Common Equity has averaged -$72.0 million across 5 years, with a median of -$72.6 million in 2025.
• Biggest YoY gain for Common Equity was 90.95% in 2025; the steepest drop was 104.6% in 2025.
• A 5-year view of Common Equity shows it stood at -$118.6 million in 2022, then rose by 10.18% to -$106.5 million in 2023, then soared by 43.51% to -$60.2 million in 2024, then surged by 44.04% to -$33.7 million in 2025, then slipped by 1.16% to -$34.1 million in 2026.
• The last three Common Equity figures came in at -$34.1 million (Q1 2026), -$33.7 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.